UBS raised the firm’s price target on Iqvia to $300 from $240 and keeps a Buy rating on the shares. The company’s Q4 results and FY24 guidance support the thesis that Iqvia’s healthy backlog and tech/data-forward offering should enable market share gains, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on IQV: